Group 1 - The Hang Seng Index Company announced the inclusion of InnoCare Pharma-B (09606) into the Hang Seng Composite Index, effective after market close on September 5, 2025, with trading starting on September 8, 2025 [1] - InnoCare Pharma-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company's key product, DB-1310, has received Fast Track designation from the FDA for treating adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed on prior EGFR TKI therapy and platinum-based chemotherapy [1] Group 2 - DB-1310 is a next-generation ADC product targeting HER3, developed using the company's proprietary DITAC technology platform [2] - Initial results from the Phase I/IIa clinical trial (NCT05785741) of DB-1310 were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, showing encouraging efficacy and manageable safety in patients with advanced solid tumors who failed standard treatments [2]
映恩生物-B获纳入恒生综合指数 有望成为港股通标的